Jury out on TauRx's claims of progress in Alzheimer's

Singapore-based TauRx Pharmaceuticals has claimed that a Phase III trial of LMTX, its tau aggregation inhibitor, had a marked benefit on key measures of Alzheimer’s disease in patients with mild or moderate forms of the disease.

The privately-held company, which is a spin-out for Scotland’s University of Aberdeen, and UK newspaper The Times, have reported the findings as evidence that the drug could soon become the first medicine given to Alzheimer’s patients to keep the disease at bay for as long as possible.

Other responses to the data, which has been presented at the 2016 Alzheimer’s Association International Conference (AAIC), have been more skeptical, including US business publication Forbes, which quoted experts doubting whether an effective treatment will materialize.